MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

被引：0
|
作者：
Neil Portman
Heloisa H. Milioli
Sarah Alexandrou
Rhiannon Coulson
Aliza Yong
Kristine J. Fernandez
Kee Ming Chia
Ensar Halilovic
Davendra Segara
Andrew Parker
Sue Haupt
Ygal Haupt
Wayne D. Tilley
Alex Swarbrick
C. Elizabeth Caldon
Elgene Lim
机构：
[1] Garvan Institute of Medical Research,St. Vincent’s Clinical School, Faculty of Medicine
[2] University of New South Wales Sydney,Tumor Suppression Laboratory
[3] Peter MacCallum Cancer Centre,Sir Peter MacCallum Department of Oncology
[4] The University of Melbourne,Adelaide Medical School
[5] Novartis Institutes of Biomedical Research,undefined
[6] The University of Adelaide,undefined
来源：
Breast Cancer Research | / 22卷
关键词：
Breast cancer; MDM2; Oestrogen receptor; CDK4/6 inhibitor; p53;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Molecular determinants of resistance to CDK4/6 inhibition in ER plus breast cancer
    Luo, F.
    Cowley, G.
    Garraway, L.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S76 - S76
  • [22] DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Nanda, Sarmistha
    Shea, Martin J.
    Schiff, Rachel
    Osborne, C. Kent
    Rimawi, Mothaffar
    Fu, Xiaoyong
    CANCER RESEARCH, 2023, 83 (05)
  • [23] MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer
    Portman, Neil
    Chen, Julia
    Lim, Elgene
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [24] CDK4/6 INHIBITION IMPROVES SURVIVAL IN ER+, HER2- BREAST CANCER
    不详
    CANCER DISCOVERY, 2015, 5 (02) : 107 - 107
  • [25] A 'real world' experience of CDK4/6 inhibition with ribociclib and endocrine therapy in hormone receptor positive metastatic breast cancer in Australia
    Lok, Sheau Wen
    Baron-Hay, Sally
    Lim, Elgene
    Blum, Robert
    Boyle, Fran
    Clarke, Kerrie
    Cuff, Katharine
    Green, Michael
    Malik, Laeeq
    Mok, Kelly
    Murray, Nick
    Nott, Louise
    Nottage, Michelle
    Tafreshi, Ali
    Tsoi, Daphne
    Yeo, Belinda
    Gibbs, Peter
    De Boer, Richard
    CANCER RESEARCH, 2020, 80 (04)
  • [26] Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
    Martinez-Saez, Olga
    Pascual, Tomas
    Braso-Maristany, Fara
    Chic, Nuria
    Gonzalez-Farre, Blanca
    Sanfeliu, Esther
    Rodriguez, Adela
    Martinez, Debora
    Galvan, Patricia
    Rodriguez, Anna Belen
    Schettini, Francesco
    Conte, Benedetta
    Vidal, Maria
    Adamo, Barbara
    Martinez, Antoni
    Munoz, Montserrat
    Moreno, Reinaldo
    Villagrasa, Patricia
    Salvador, Fernando
    Ciruelos, Eva M.
    Faull, Iris
    Odegaard, Justin I.
    Prat, Aleix
    NPJ BREAST CANCER, 2021, 7 (01)
  • [27] Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
    Olga Martínez-Sáez
    Tomás Pascual
    Fara Brasó-Maristany
    Nuria Chic
    Blanca González-Farré
    Esther Sanfeliu
    Adela Rodríguez
    Débora Martínez
    Patricia Galván
    Anna Belén Rodríguez
    Francesco Schettini
    Benedetta Conte
    Maria Vidal
    Barbara Adamo
    Antoni Martínez
    Montserrat Muñoz
    Reinaldo Moreno
    Patricia Villagrasa
    Fernando Salvador
    Eva M. Ciruelos
    Iris Faull
    Justin I. Odegaard
    Aleix Prat
    npj Breast Cancer, 7
  • [28] CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
    Garrido-Castro A.C.
    Goel S.
    Current Breast Cancer Reports, 2017, 9 (1) : 26 - 33
  • [29] Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
    Schedin, Troy B.
    Borges, Virginia F.
    Shagisultanova, Elena
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2018, 2018
  • [30] Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
    Scott, Susan Combs
    Lee, Sarah S.
    Abraham, Jame
    SEMINARS IN ONCOLOGY, 2017, 44 (06) : 385 - 394
12345